Can You Get a Retatrutide Prescription? Doctors, Telehealth and Compounding

No doctor can write a retatrutide prescription that a pharmacy can legally fill, as of October 31, 2026. Six Phase 3 trials have now reported positive results, but retatrutide is still investigational and no regulator anywhere has approved it. The FDA also says it "cannot be used in compounding under federal law." A doctor can still do 3 useful things: refer you to a trial, ask Lilly for expanded access if you qualify, or prescribe an approved drug from the same family.

This page is about the prescription itself: what a doctor, a telehealth site, a compounding pharmacy and an insurer can and can't do for you. If you want every route to the drug ranked by risk, that's our how to get retatrutide page, and where to buy retatrutide covers the sellers.

Why there's no retatrutide prescription yet

A prescription tells a pharmacy to dispense a drug. In the US it needs an FDA-approved product to fill it, or an ingredient it's allowed to compound. Retatrutide has neither.

The results are why people ask. TRIUMPH-1 is in the New England Journal of Medicine, and on October 28, 2026 TRANSCEND-T2D-2 showed 12 mg beating Ozempic 2 mg on weight, 20.9% against 9.4% at 80 weeks (efficacy estimand, Lilly's release). None of that makes a label, a dose or a prescription.

Lilly's October 2026 FAQ says retatrutide "has not been reviewed or approved by the FDA or any regulatory agency in the world, and no one can legally sell it for human use." Its March 2026 release calls it "legally available only to participants in Lilly's clinical trials." Our is retatrutide legal page has the rest of the legal picture.

Lilly hasn't said it has filed for approval. It last said, on September 29, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA). On October 2, 2026, the FDA decided that retatrutide is a drug, not a biological product, so an application would need to be filed under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly's appeal on that question is pending in the Seventh Circuit, and we found no ruling as of October 31, 2026. Until the FDA approves an application, there's no labeled dose and nothing for a pharmacy to stock, so the honest answer to "can you prescribe me reta?" is no. Our FDA approval and release date pages follow the filing.

What a doctor can do for you today

Quite a lot, as long as the goal is treatment and not retatrutide itself. As of October 31, 2026, nobody in this table can get you legal retatrutide outside a Lilly trial or expanded access.

Trials come first. When we pulled the ClinicalTrials.gov registry on October 31, 2026, 2 retatrutide studies were recruiting, and none of the TRIUMPH or TRANSCEND trials was. One is Lilly's SYNERGY-Outcomes study in adults with fatty liver disease (MASLD) at higher risk of liver complications. It lists 502 recruiting sites in 34 countries or territories, 137 of them in the US, and requires liver fat of 8% or more and liver stiffness of 10 kPa or more (under 20). The other is from a different sponsor at 1 site in Shenzhen, China. The retatrutide clinical trials page tracks what's open.

One Reddit thread asks whether to give retatrutide to a mother with diabetes and fatty liver. What a doctor can do with that question is check whether she fits a study like SYNERGY-Outcomes, which compares retatrutide and tirzepatide each against placebo, and treat the diabetes now with an approved drug.

Expanded access is the second route, and it's narrow. Lilly's single-patient listing (NCT07629401) is for adults whose BMI is still 35 or higher despite taking and tolerating the highest available dose of an approved weight-management drug, who have 2 or more serious or life-threatening obesity-related complications, and who can't join a trial. Every standard option, bariatric surgery included, has to have been discussed. Your doctor calls the Lilly Answers Center at 1-800-545-5979; approval depends on location, supply and individual review.

Our read: expanded access is built for people who have already taken an approved drug at its highest available dose. If you haven't tried tirzepatide or semaglutide at its top dose, the realistic prescription today is one of those. Zepbound against retatrutide lays out how the two compare.

Can retatrutide be compounded?

Not legally in the US. Under section 503A of federal drug law, a compounding pharmacy can make a drug from a bulk ingredient only if the ingredient meets a USP or NF monograph (an official quality standard), is an ingredient of an FDA-approved drug, or is on the FDA's 503A bulks list. Outsourcing facilities work under section 503B, where the ingredient has to be on the 503B bulks list or the finished drug on the FDA's drug shortage list.

The FDA applied those tests to retatrutide in a warning letter dated September 9, 2025. Retatrutide "is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list." It isn't on the 503B list either, and no retatrutide drug is on the shortage list. The letter concluded the seller's "compounded retatrutide drug products are unapproved new drugs and misbranded drugs." The FDA's concerns page, current as of October 1, 2026, still says retatrutide "cannot be used in compounding under federal law."

Compounded semaglutide and tirzepatide differ because both are ingredients of approved drugs, so they pass the second test. Retatrutide isn't part of any approved drug, so it fails that test along with the other two. "Compounded retatrutide" describes where a seller says a vial came from, not a legal product. Lilly's October 28 release goes further: "Anyone purporting to sell retatrutide to consumers is breaking the law." The FDA says it has also warned ingredient distributors and outsourcing facilities. On August 12, 2026, Lilly filed 6 lawsuits against US sellers, including compounding pharmacies and medical spas.

Telehealth sites that offer a reta prescription

Some telehealth sites advertise a retatrutide or "reta" prescription, usually as a compounded injection. The FDA says it has warned telehealth companies for marketing retatrutide, including directly to consumers. Such a prescription can't be filled with a legal product, so whatever arrives came from an illegal compounder or a peptide seller.

The FDA's warning signs for online GLP-1 sellers include claiming a compounded drug is the same as an approved one, or skipping a screening and a prescription from a licensed doctor. On March 3, 2026 it announced 30 warning letters to telehealth companies over compounded GLP-1 marketing. That release didn't name retatrutide, which can't legally be compounded at all.

Before you pay a site that offers retatrutide, ask these questions:

1. Which pharmacy fills it, and in which state is it licensed?
2. Is it described as compounded? The FDA says retatrutide can't be.
3. Is it presented as Lilly's drug? Lilly supplies it only through trials and expanded access.
4. Did a licensed doctor review your history, or was it a checkout form?

A doctor's name on the label doesn't change what's in the vial. In a September 14, 2026 alert, Australia's TGA reported testing an unmarked vial sold as retatrutide after a person had uncontrollable vomiting, a torn esophagus and hospital treatment. It held no retatrutide, and semaglutide at about 8 times the level in approved semaglutide products. Victoria's Chief Health Officer reported 6 cases of acute liver injury since January 2026 in people who used a product labeled Retatrutide, possibly from a contaminant. A BMJ Case Reports paper from October 7, 2026 describes a woman in her mid-20s with 5 days of refractory nausea and vomiting after 4 weekly injections of an unverified product reported to contain retatrutide, given by a non-medical "life coach." If you're weighing retatrutide for sale from a peptide seller anyway, the checks that matter are batch-specific lab reports, which our retatrutide testing page explains, and none of them makes the product legal.

Is retatrutide covered by insurance?

No. Insurers pay for approved drugs, and there's no approved retatrutide. That includes Medicare's GLP-1 Bridge, which runs from July 1, 2026 to December 31, 2027 and covers Zepbound KwikPen, Foundayo and Wegovy for $50 a month with prior authorization. Retatrutide isn't on it. The Bridge is also closed to people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease.

Trials are a separate question, and your plan doesn't have to pay for the study drug. Federal law (42 U.S.C. 300gg-8) stops plans from denying routine patient costs in an approved trial, but only for cancer or another life-threatening condition, and "routine patient costs" excludes "the investigational item, device, or service, itself." Ask the trial site in writing what the sponsor pays for.

Will insurance cover retatrutide after approval? Nobody knows yet. Lilly hasn't set a price; its FAQ says it plans to price retatrutide "to reflect the overall value to the healthcare system." The closest precedent is Zepbound, approved in November 2023 with a list price of $1,059.87; by May 28, 2026, all 3 of the largest pharmacy benefit managers covered Lilly's obesity medicines.

The makers' own pages listed these US prices for the approved alternatives on September 27, 2026. We re-checked the Zepbound, Foundayo and Wegovy self-pay prices on October 31 and they hadn't changed. The Wegovy new-patient price, Foundayo's reduced 2.5 mg and 5.5 mg prices and the Zepbound savings card terms all end December 31, 2026.

Our read: expect retatrutide coverage to be decided plan by plan at first, with self-pay as the fallback, the path Zepbound took after its 2023 approval. Lilly hasn't said so. Our retatrutide price page tracks what's known about cost.

Can a GP prescribe retatrutide in the UK, Canada or Australia?

Not in any of the three, as of October 2026. None of these regulators has approved retatrutide, so there's no approved product for a GP to prescribe.

The UK's MHRA said on July 24, 2026: "It has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally." Health Canada's April 9, 2026 advisory lists retatrutide among unauthorized injectable peptides it has seized, and authorized drugs there carry an 8-digit Drug Identification Number (DIN) that retatrutide lacks. Australia's TGA named retatrutide among unapproved peptide products in an April 13, 2026 advisory aimed partly at prescribers, and says practitioners who compound, prescribe or supply them must meet all regulatory requirements. Our availability by country page has the details.

When will retatrutide be prescription only?

As soon as it's approved, almost certainly. Every approved drug in this family, Zepbound and Wegovy included, needs a prescription, and the reasoning in the FDA's September 2025 letter points the same way for retatrutide: it's meant for conditions people can't diagnose and treat without a doctor, so no label could give a layperson adequate directions for use. Nothing containing retatrutide is approved for over-the-counter sale either, so a site that sells it without a prescription is selling an unapproved product.

Search results for a clinic that "has it" don't change any of this; retatrutide near me explains what those listings are. The step that counts now is an appointment with your doctor to record your weight, your BMI and which approved drugs you've tried at what dose, because trial screening and Lilly's expanded access criteria both ask for exactly that history.